Abstract | PURPOSE: METHODS: Four consecutive patients with periocular actinic keratosis who were treated with topical 3% diclofenac gel twice daily for up to 4 months were included in the study. Patients were reviewed at 1 and 2 months and then as clinically required up to 13 months after treatment. RESULTS: All 4 patients had biopsy-proven actinic keratosis. Three of the 4 patients tolerated the therapy well. In 1 patient, an adverse reaction developed, with erythema, crusting, and scaling after 2 months of therapy, which resolved within a month of discontinuing topical diclofenac. In all the patients, a visible decrease in lesion severity was seen after 1 month, and complete resolution, within 4 months. Recurrences occurred in 2 patients at 4 months and 7 months after treatment. These were successfully managed, in one patient, by excision, and in the other, with further 3% diclofenac gel followed by cryotherapy. CONCLUSION: The use of 3% diclofenac gel in extraocular sites has been widely described in the dermatology literature. However, no published reports exist of its use in ophthalmology. It may be a useful therapeutic option when used alone in patients with localized disease or to reduce the size of larger, more-diffuse lesions before excision or cryotherapy, leading to improved cosmesis. Furthermore, it may also be useful in patients prone to actinic keratoses, such as organ-transplant recipients, to reduce the need for multiple excision procedures or uncomfortable ablative techniques.
|
Authors | Ruchika Batra, Sathya Sundararajan, Soupramanien Sandramouli |
Journal | Ophthalmic plastic and reconstructive surgery
(Ophthalmic Plast Reconstr Surg)
2012 Jan-Feb
Vol. 28
Issue 1
Pg. 1-3
ISSN: 1537-2677 [Electronic] United States |
PMID | 21785377
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Inflammatory Agents, Non-Steroidal
- Gels
- Diclofenac
|
Topics |
- Administration, Topical
- Aged
- Anti-Inflammatory Agents, Non-Steroidal
(administration & dosage)
- Diclofenac
(administration & dosage)
- Eyelid Neoplasms
(drug therapy)
- Female
- Gels
- Humans
- Keratosis, Actinic
(drug therapy)
- Male
- Middle Aged
- Precancerous Conditions
(drug therapy)
|